Dr. Reddy's Laboratories 과거 수익 실적

과거 기준 확인 2/6

Dr. Reddy's Laboratories은 연평균 27.1%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 증가했으며, 연간 1.2%였습니다. 매출은 연평균 12.1%의 비율로 증가했습니다. Dr. Reddy's Laboratories의 자기자본이익률은 17.5%이고 순이익률은 17.8%입니다.

주요 정보

27.1%

수익 성장률

27.0%

EPS 성장률

Pharmaceuticals 산업 성장	6.0%
매출 성장률	12.1%
자기자본 수익률	17.5%
순이익	17.8%
최근 수익 업데이트	30 Sep 2024

최근 과거 실적 업데이트

Recent updates

Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy

Aug 13

Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements

Nov 29

Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook

Oct 27

Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed

Jan 20

Dr. Reddy's Needs Time For Generics Sales To Replace Sputnik Revenue

Nov 07

Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M

Jul 28

Dr. Reddy's launches generic drugs for allergies in US

Jul 22

Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases

Jul 05

수익 및 비용 분석

Dr. Reddy's Laboratories 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

NYSE:RDY 수익, 비용 및 수입 (INR Millions )
날짜	수익	수익	G+A 비용	R&D 비용
30 Sep 24	299,867	53,332	86,402	25,906
30 Jun 24	288,507	55,579	82,190	24,082
31 Mar 24	279,164	55,684	77,201	22,873
31 Dec 23	271,302	52,206	74,717	21,362
30 Sep 23	266,854	50,888	72,470	20,618
30 Jun 23	261,109	47,216	70,235	20,040
31 Mar 23	245,879	45,067	68,026	19,381
31 Dec 22	237,279	36,350	65,708	18,341
30 Sep 22	222,776	30,944	63,138	17,679
30 Jun 22	217,351	29,736	62,529	17,273
31 Mar 22	214,391	23,568	62,081	17,482
31 Dec 21	207,307	26,317	60,717	17,250
30 Sep 21	203,406	19,450	59,693	17,199
30 Jun 21	194,741	17,153	56,849	17,095
31 Mar 21	189,722	17,238	54,650	16,541
31 Dec 20	186,756	21,256	52,457	16,637
30 Sep 20	181,298	15,361	50,740	16,478
30 Jun 20	180,340	18,663	50,850	15,781
31 Mar 20	174,600	19,498	50,129	15,410
31 Dec 19	170,448	16,200	50,246	14,882
30 Sep 19	165,110	26,749	49,484	14,601
30 Jun 19	155,079	20,862	48,639	15,059
31 Mar 19	153,851	18,795	48,680	15,607
31 Dec 18	149,034	17,473	48,400	16,293
30 Sep 18	148,594	15,965	48,540	17,292
30 Jun 18	145,903	13,776	47,200	17,347
31 Mar 18	141,855	9,806	46,857	18,265
31 Dec 17	141,827	9,909	45,370	18,458
30 Sep 17	140,588	11,266	44,663	18,747
30 Jun 17	140,907	11,367	45,405	19,786
31 Mar 17	139,870	12,039	46,300	19,513
31 Dec 16	141,269	9,660	46,961	19,718
30 Sep 16	144,127	10,751	47,659	18,857
30 Jun 16	148,410	15,019	46,943	18,116
31 Mar 16	153,866	20,013	45,641	17,701
31 Dec 15	155,850	24,456	44,152	18,100
30 Sep 15	154,602	24,409	43,264	18,321
30 Jun 15	150,592	22,932	42,879	17,961
31 Mar 15	147,360	22,179	42,076	17,329
31 Dec 14	143,474	21,806	42,810	16,289
30 Sep 14	140,380	22,247	42,102	14,952
30 Jun 14	138,076	23,409	41,165	13,847
31 Mar 14	132,170	21,515	38,783	12,402
31 Dec 13	130,043	22,409	37,695	10,852

양질의 수익: RDY 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: RDY 의 현재 순이익 이익률 (17.8%) 작년보다 낮습니다 (19.1%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: RDY 의 수익은 지난 5년 동안 매년 27.1% 씩 크게 증가했습니다.

성장 가속화: 지난 1년간 RDY 의 수익 증가율( 4.8% )은 5년 평균( 27.1% 보다 낮습니다. 년도).

수익 대 산업: 지난 1년간 RDY 수익 성장( 4.8% )은 Pharmaceuticals 업계 54.6% 능가하지 못했습니다. 54.6%.

자기자본 수익률

높은 ROE: RDY 의 자본 수익률( 17.5% )은 낮음으로 간주됩니다.

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/23 10:13
장 마감 주가	2024/12/20 00:00
수익	2024/09/30
연간 수익	2024/03/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Dr. Reddy's Laboratories Limited 77 애널리스트 중 38 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Prashant Nair	Ambit Capital
Sriraam Rathi	Anand Rathi Shares and Stock Brokers Limited
null null	Anand Rathi Shares and Stock Brokers Limited

Dr. Reddy's Laboratories 과거 수익 실적

과거 기준 확인 2/6

주요 정보

최근 과거 실적 업데이트

Dr. Reddy's Laboratories Limited to Report Q2, 2025 Results on Nov 05, 2024

Dr. Reddy's Laboratories Limited to Report Q1, 2025 Results on Jul 27, 2024

Dr. Reddy's Laboratories Limited to Report Q4, 2024 Results on May 07, 2024

Dr. Reddy's Laboratories Limited to Report Q3, 2024 Results on Jan 30, 2024

Dr. Reddy's Laboratories Limited to Report Q2, 2024 Results on Oct 27, 2023

Dr. Reddy's Laboratories Limited to Report Q1, 2024 Results on Jul 26, 2023

Recent updates

Dr. Reddy's Laboratories Ltd. Launches Toripalimab in India

Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laboratories Limited Complaint Made Public in the United States District Court for the District of New Jersey

Dr. Reddy's Laboratories Limited to Report Q2, 2025 Results on Nov 05, 2024

Dr. Reddy's and Nestle Health Science Appoints Mansi Khanna as Chief Operating Officer

Dr. Reddy's Laboratories: Economic Factors Square Off To Reiterate Buy

Dr. Reddy's Laboratories Limited Approves Dividend for the Fiscal Year 2024

Dr. Reddy's Receives Positive CHMP Opinion from European Medicines Agency for Its Proposed Rituximab Biosimilar

Dr. Reddy's Laboratories Limited to Report Q1, 2025 Results on Jul 27, 2024

Dr. Reddy's Laboratories Limited Announces Appointment of Milan Kalawadia as Chief Executive Officer, North America

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 29, 2024

Dr. Reddy's Laboratories Limited Announces Chief Financial Officer Changes

Dr. Reddy's Laboratories Limited Announces Executive Changes

Dr. Reddy's Laboratories Limited to Report Q4, 2024 Results on May 07, 2024

Walgreen Co., Kroger Specialty Pharmacy, Inc. and CVS Pharmacy, Inc. File Complaint Against Dr. Reddy's Laboratories, Inc. and Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Denies in Race to Acquire Novartis' Stake in Novartis India

Dr Reddy's Reportedly May Join Race to Acquire Novartis' India Arm

Dr. Reddy's Laboratories Limited Appoints Sanjiv Mehta as A Non-Executive Independent Member of the Board

Dr Reddy's Laboratories Reportedly Eyes Mega Brand in UK

Dr. Reddy's Laboratories Limited Announces Change in Management

Dr. Reddy's Laboratories Limited Announces Appointment of Sanjiv Mehta as Additional Director

Dr. Reddy's Laboratories Limited to Report Q3, 2024 Results on Jan 30, 2024

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed GMP and Pre-Approval Inspection

Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements

Dr. Reddy's Laboratories Ltd. Announces the Roll-Out of Nerivio in India

Dr. Reddy's: Continued Q2 Earnings Growth, Supports Long-Term Investment Outlook

Dr. Reddy's Laboratories Limited to Report Q2, 2024 Results on Oct 27, 2023

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Bain Capital Reportedly Approaches Dr. Reddy's Laboratories to Explore Joint Bid to Buy Out the Promoters of Cipla

Dr. Reddy's: Growth Supported By New Labels, Profitability

Dr. Reddy's Laboratories Ltd. Announces its Launch of Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S

Dr. Reddy's Laboratories Limited Announces Resignation of Mukesh Rathi as Chief Information Officer

Dr. Reddy's Laboratories Limited Approves Dividend for the Financial Year Ended March 31, 2023

Dr. Reddy's Laboratories Limited Announces Management Changes

Dr. Reddy's Laboratories Limited Announces Its Proposed Rituximab Biosimilar Application Acceptance for Review by USFDA, EMA and MHRA

Dr. Reddy's Laboratories Limited to Report Q1, 2024 Results on Jul 26, 2023

Dr. Reddy's Laboratories: Unpacking The Critical Factors, Reiterate Buy

Dr. Reddy's Laboratories Limited Completes Phase I Study (IV Route) of DRL_TC

Dr. Reddy's Laboratories Limited Reports Impairment Charges for the Fourth Quarter Ended March 31, 2023

Dr. Reddy's Laboratories Limited, Annual General Meeting, Jul 27, 2023

Dr. Reddy's Laboratories Limited Announces the Launch of Regadenoson Injection 0.4 Mg/5 Ml in the U.S

Dr. Reddy's Laboratories: Positive Q3 Results, Growth Supportive Of Buy

Dr. Reddy's Laboratories Limited Announces the Launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market

Dr. Reddy's Laboratories Limited Completes Full Set of Clinical Studies of Its Rituximab Biosimilar for Filing in the U.S., Europe

Dr. Reddy's prepare to file for Rituxan biosimilar in US, EU as trials completed

Dr. Reddy’S Launches In-House Palbociclib (Primcyv®) to Widen Access to High-Quality Breast Cancer Drug

Dr. Reddy's Laboratories Limited Announces Resignation of Allan Grant Oberman as an Independent Director

Dr. Reddy's Laboratories Provides Updates on Litigation

Dr. Reddy's Laboratories Limited to Report Q3, 2023 Results on Jan 25, 2023

Dr. Reddy s Laboratories Ltd. Announces Tocilizumab Biosimilar Candidate, DRL_TC, Successfully Met Its Primary and Secondary Endpoints in A Phase 1 Study

Dr. Reddy's Needs Time For Generics Sales To Replace Sputnik Revenue

Dr. Reddy's Laboratories Limited Announces Change in Directorate

Dr. Reddy's Laboratories Limited Appoints Mr. Arun Madhavan Kumar as an Independent Director

Dr. Reddy's Laboratories Limited to Report Q2, 2023 Results on Oct 28, 2022

Dr. Reddy's Laboratories Limited Informs Bruce L A Carter, Independent Director of the Company Has Ceased to Be A Director

Dr. Reddy's Laboratories Limited Appoints Arun Madhavan Kumar as an Independent Additional Director

Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M

Dr. Reddy's Laboratories Announces the Launch of Bortezomib for Injection, 3.5 Mg Single-Dose Vial in the U.S. Market

Dr. Reddy's Laboratories Limited Announces the First-to-Market Launch of Over-the-Counter, Store-Brand Equivalent of Allegra-D® 24 Hr in the U.S. Market

Dr. Reddy's launches generic drugs for allergies in US

Dr. Reddy's Laboratories Limited Announces United States Food & Drug Administration Completed Pre-Approval Inspection At Formulations Manufacturing Facility FTO 11 in Srikakulam, Andhra Pradesh

Dr. Reddy's, EQRx team up to develop drugs for cancer, immune-inflammatory diseases

J. B. Chemicals & Pharmaceuticals Limited (BSE:506943) agreed to acquire Portfolio of four paediatric brands from Dr. Reddy's Laboratories Limited (BSE:500124) for INR 98 million.

Dr. Reddy's Laboratories Limited to Report Q1, 2023 Results on Jul 28, 2022

Dr. Reddy's Laboratories Limited Announces Settlement Agreement with Respect to Buprenorphine and Naloxone Sublingual Film

Dr. Reddy's Laboratories Announces the Launch of the Generic Version of Nexavar (Sorafenib) Tablets, USP, 200 Mg in the U.S. Market

Dr. Reddy’S Laboratories Ltd. Announces the Launch of Pemetrexed for Injection, 100 Mg and 500 Mg Single-Dose Vials, the Generic Equivalent of Alimta® (Pemetrexed for Injection) in the U.S. Market Approved by the U.S. Food and Drug Administration

Torrent Pharmaceuticals Limited (BSE:500420) entered into an agreement to acquire Styptovit-E, Finast, Finast-T and Dynapress brands from Dr. Reddy's Laboratories Limited (BSE:500124).

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch Ketorolac Tromethamine Tablets USP, 10 MG in the U.S. Market

Dr. Reddy's Laboratories and Senores Pharmaceuticals, Inc. Announce the Launch Ketorolac Tromethamine Tablets USP, 10 MG in the U.S. Market